FDAFinal Rule
Regulatory Hearing Before the Food and Drug Administration; CFR Correction
HealthcareOther
Ad Space (leaderboard)
Summary
The FDA is making a technical correction to its regulatory hearing procedures. This update ensures that the FDA's official rules are accurate and consistent, which helps ensure fair processes when the agency holds hearings about food, drug, and medical device decisions.
Key Points
- 1This is a correction to existing FDA hearing procedures, not a completely new rule
- 2The change helps clarify how the FDA conducts regulatory hearings fairly and transparently
- 3Companies and individuals who request FDA hearings will have clearer procedures to follow
- 4The correction was needed to fix errors or inconsistencies in the previously published rules
- 5This update affects the formal process people use to challenge FDA decisions about products
Impact Assessment
If you are a Manufacturer or Healthcare Provider seeking FDA approval or contesting an FDA decision, this means the hearing process procedures are now clarified and consistently applied, ensuring fairer treatment during regulatory proceedings.
Impact Level
Routine
Geographic Scope
National
Compliance Cost
Minimal
Who is Affected
ManufacturersHealthcare ProvidersImporters/Exporters
Key Dates
Published
July 28, 2025
Regulatory Connections
Authorized By
Amends CFR Sections
21 CFR Part 16
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
Ad Space (rectangle)